Literature DB >> 7272933

Corticosteroids for elderly patients with breast cancer.

M J Minton, R K Knight, R D Rubens, J L Hayward.   

Abstract

Ninety-one assessable elderly women (greater than 65 years) with advanced breast cancer were treated with prednisolone 15 mg (or cortisone 75 mg) daily after primary endocrine treatment (estrogens, androgens or tamoxifen). Thirteen (14%) achieved an objective regression, and 19 (21%) others showed no change for greater than or equal to six months. Hence, 32 patients (35%) had control of disease for about one year. Responses were mainly in soft tissue and skeletal lesions and were independent of response to prior endocrine treatment. Toxicity was low. Low-dose corticosteroid treatment is of value in controlling advanced breast cancer in elderly women.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7272933     DOI: 10.1002/1097-0142(19810815)48:4<883::aid-cncr2820480404>3.0.co;2-v

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

1.  Corticosteroids in advanced cancer.

Authors:  R Twycross
Journal:  BMJ       Date:  1992-10-24

2.  Mechanisms in endocrine therapy of bone metastases.

Authors:  B A Stoll
Journal:  J R Soc Med       Date:  1985       Impact factor: 5.344

Review 3.  Endocrine therapy for advanced breast cancer: a review.

Authors:  H B Muss
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

Review 4.  The risks and benefits of corticosteroids in advanced cancer.

Authors:  R Twycross
Journal:  Drug Saf       Date:  1994-09       Impact factor: 5.606

5.  Prednisolone improves the response to primary endocrine treatment for advanced breast cancer.

Authors:  R D Rubens; C L Tinson; R E Coleman; R K Knight; D Tong; P J Winter; W R North
Journal:  Br J Cancer       Date:  1988-11       Impact factor: 7.640

Review 6.  Systematic review of the clinical effect of glucocorticoids on nonhematologic malignancy.

Authors:  Bruce D Keith
Journal:  BMC Cancer       Date:  2008-03-28       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.